A phase II trial of erlotinib in patients with EGFR wild-type advanced non-small-cell lung cancer

被引：0
|
作者：
Takashi Kobayashi
Tomonobu Koizumi
Toshihide Agatsuma
Masanori Yasuo
Kenji Tsushima
Keishi Kubo
Seiichiro Eda
Hiroshi Kuraishi
Shigeru Koyama
Tsutomu Hachiya
Nariaki Ohura
机构：
[1] Shinshu University Hospital,Comprehensive Cancer Center, Division of Clinical Oncology, Shinshu University School of Medicine
[2] Shinshu University School of Medicine,First Department of Internal Medicine
[3] Matsumoto Kyoritsu Hospital,Respiratory Division
[4] Nagano Red Cross Hospital,Respiratory Division
[5] Suwa Red Cross Hospital,Respiratory Division
[6] Saku Central Hospital,Respiratory Division
来源：
Cancer Chemotherapy and Pharmacology | 2012年 / 69卷
关键词：
Chemo-refractory; Salvage therapy; EGFR-sensitive mutation; Chemotherapy; NSCLC;
D O I：
暂无
中图分类号：
学科分类号：
摘要：
引用
收藏
页码：1241 / 1246
页数：5
相关论文
共 50 条
  • [1] A phase II trial of erlotinib in patients with EGFR wild-type advanced non-small-cell lung cancer
    Kobayashi, Takashi
    Koizumi, Tomonobu
    Agatsuma, Toshihide
    Yasuo, Masanori
    Tsushima, Kenji
    Kubo, Keishi
    Eda, Seiichiro
    Kuraishi, Hiroshi
    Koyama, Shigeru
    Hachiya, Tsutomu
    Ohura, Nariaki
    [J]. CANCER CHEMOTHERAPY AND PHARMACOLOGY, 2012, 69 (05) : 1241 - 1246
  • [2] Phase II Trial of Erlotinib Monotherapy for Pretreated Elderly Patients with Advanced EGFR Wild-Type Non-Small-Cell Lung Cancer
    Minemura, Hiroyuki
    Yokouchi, Hiroshi
    Azuma, Keisuke
    Hirai, Kenichiro
    Sekine, Satoko
    Oshima, Kengo
    Kanazawa, Kenya
    Tanino, Yoshinori
    Inokoshi, Yayoi
    Ishii, Taeko
    Katsuura, Yutaka
    Oishi, Akio
    Ishida, Takashi
    Munakata, Mitsuru
    [J]. JOURNAL OF THORACIC ONCOLOGY, 2015, 10 (09) : S547 - S547
  • [3] Role of erlotinib in the treatment of advanced non-small-cell lung cancer patients with EGFR wild-type tumors
    Braun, Eduardo
    Bonomi, Philip
    [J]. LUNG CANCER MANAGEMENT, 2014, 3 (01) : 101 - 116
  • [4] A phase II trial of erlotinib monotherapy for pretreated elderly patients with advanced EGFR wild-type non-small cell lung cancer Cancer
    Minemura H.
    Yokouchi H.
    Azuma K.
    Hirai K.-I.
    Sekine S.
    Oshima K.
    Kanazawa K.
    Tanino Y.
    Inokoshi Y.
    Ishii T.
    Katsuura Y.
    Oishi A.
    Ishida T.
    Munakata M.
    [J]. BMC Research Notes, 8 (1)
  • [5] Randomized Phase II Trial of Seribantumab in Combination with Erlotinib in Patients with EGFR Wild-Type Non-Small Cell Lung Cancer
    Sequist, Lecia, V
    Gray, Jhanelle Elaine
    Harb, Wael A.
    Lopez-Chavez, Ariel
    Doebele, Robert C.
    Modiano, Manuel R.
    Jackman, David Michael
    Baggstrom, Maria Quintos
    Atmaca, Akin
    Felip, Enriqueta
    Provencio, Mariano
    Cobo, Manuel
    Adiwijaya, Bambang
    Kuesters, Geoffrey
    Kamoun, Walid S.
    Andreas, Karen
    Pipas, J. Marc
    Santillana, Sergio
    Cho, Byoung Chul
    Park, Keunchil
    Shepherd, Frances A.
    [J]. ONCOLOGIST, 2019, 24 (08): : 1095 - 1102
  • [6] Randomized Phase 2 Trial of Seribantumab in Combination with Erlotinib in Patients with EGFR Wild-Type Non-Small Cell Lung Cancer
    Sequist, L.
    Gray, J.
    Harb, W.
    Doebele, R.
    Modiano, M.
    Jackman, D.
    Baggstrom, M.
    Atmaca, A.
    Felip, E.
    Provencio, M.
    Cobo Dols, M.
    Adiwijaya, B.
    Kuesters, G.
    Kamoun, W.
    Andreas, K.
    Pipas, J.
    Santillana, S.
    Cho, B. C.
    Park, K.
    Shepherd, F.
    [J]. JOURNAL OF THORACIC ONCOLOGY, 2018, 13 (10) : S596 - S596
  • [7] Safety and Efficacy of Dacomitinib in Korean Patients with KRAS Wild-Type Advanced Non-Small-Cell Lung Cancer Refractory to Chemotherapy and Erlotinib or Gefitinib A Phase I/II Trial
    Park, Keunchil
    Cho, Byoung C.
    Kim, Dong-Wan
    Ahn, Myung-Ju
    Lee, Sang-Yoon
    Gernhardt, Diana
    Taylor, Ian
    Campbell, Alicyn K.
    Zhang, Hui
    Giri, Nagdeep
    Letrent, Stephen P.
    O'Connell, Joseph
    Heo, Dae S.
    [J]. JOURNAL OF THORACIC ONCOLOGY, 2014, 9 (10) : 1523 - 1531
  • [8] Randomized Phase II Trial of Onartuzumab in Combination With Erlotinib in Patients With Advanced Non-Small-Cell Lung Cancer
    Spigel, David R.
    Ervin, Thomas J.
    Ramlau, Rodryg A.
    Daniel, Davey B.
    Goldschmidt, Jerome H., Jr.
    Blumenschein, George R., Jr.
    Krzakowski, Maciej J.
    Robinet, Gilles
    Godbert, Benoit
    Barlesi, Fabrice
    Govindan, Ramaswamy
    Patel, Taral
    Orlov, Sergey V.
    Wertheim, Michael S.
    Yu, Wei
    Zha, Jiping
    Yauch, Robert L.
    Patel, Premal H.
    Phan, See-Chun
    Peterson, Amy C.
    [J]. JOURNAL OF CLINICAL ONCOLOGY, 2013, 31 (32) : 4105 - +
  • [9] Phase II Study of Amrubicin Plus Erlotinib in Previously Treated, Advanced Non-Small Cell Lung Cancer Patients with Wild-Type EGFR: TORG 1320
    Hosokawa, S.
    Otani, S.
    Sasaki, J.
    Fukui, T.
    Nakahara, Y.
    Bessho, A.
    Fukamatsu, N.
    Nakamura, Y.
    Kasai, T.
    Sugiyama, T.
    Tokitho, T.
    Seki, N.
    Hamada, A.
    Masuda, N.
    Okamoto, H.
    [J]. JOURNAL OF THORACIC ONCOLOGY, 2018, 13 (10) : S881 - S882
  • [10] Erlotinib versus docetaxel as second-line treatment of patients with advanced non-small-cell lung cancer and wild-type EGFR tumours (TAILOR): a randomised controlled trial
    Garassino, Marina Chiara
    Martelli, Olga
    Broggini, Massimo
    Farina, Gabriella
    Veronese, Silvio
    Rulli, Eliana
    Bianchi, Filippo
    Bettini, Anna
    Longo, Flavia
    Moscetti, Luca
    Tomirotti, Maurizio
    Marabese, Mirko
    Ganzinelli, Monica
    Lauricella, Calogero
    Labianca, Roberto
    Floriani, Irene
    Giaccone, Giuseppe
    Torri, Valter
    Scanni, Alberto
    Marsoni, Silvia
    [J]. LANCET ONCOLOGY, 2013, 14 (10): : 981 - 988
12345